BOSTON — March 29, 2017 — Partners HealthCare, the nation’s largest academic research enterprise, today announced the third annual World Medical Innovation Forum, which will bring together nearly 1,000 international cardiovascular innovation decision-makers from industry, investment, clinical and research communities from May 1 to May 3, 2017 in Boston.
The focus of the Forum is the new technologies and systems that are transforming the largest market in healthcare. Keynoters include the CEOs of Amgen, Boston Scientific, Medtronic, Philips, Cardinal Health, Abiomed, Alnylam, Bard, Edwards, Medicines Company, Moderna, MyoKardia, Yumanity, Zoll, Boehringer Ingelheim, American Heart Association, GE Healthcare, Siemens Healthcare, and GE Ventures. They will be joined by top investors, the head of National Heart Lung and Blood Institute, Gary Gibbons, MD, the former FDA commissioner, Robert Califf, MD, and key leaders from the Centers for Medicare and Medicaid Services. There will be more than 120 speakers in total—all experts from industry, government, the investment community and Harvard Medical School. World Forum attendees include senior executives, investors, entrepreneurs, clinicians and scientists.
“The Forum will highlight the remarkable convergence occurring across different industries around the redesign of cardiovascular care,” says Calum MacRae, MD, PhD, Chief of Cardiovascular Medicine at Brigham and Women’s Hospital and Associate Professor of Medicine at Harvard Medical School. “The outcomes of this cooperation between academia and industry will impact the lives of millions of patients worldwide.”
The outcomes of this cooperation between academia and industry will impact the lives of millions of patients worldwideCalum MacRae, MD, PhD Chief of Cardiovascular Medicine at Brigham and Women’s Hospital and Associate Professor of Medicine at Harvard Medical School
Over three days, the Forum will review in detail the emerging cardiovascular therapies, ’omics, digital diagnostics, education and engagement with new delivery platforms to that will become the model of care for cardiovascular and related metabolic diseases.
The Forum is co-chaired by MacRae and Anthony Rosenzweig, MD, Chief, Cardiology Division at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. Academic speakers will include dozens of senior Harvard Medical School-appointed clinicians and investigators from Brigham and Women’s Hospital, Massachusetts General Hospital and Newton-Wellesley Hospital including the Presidents of all three hospitals.
“The changing spectrum of heart disease has produced new clinical needs, and marshaling an effective response will require cooperation among a diverse array of stakeholders. Technology, patient insights and clinical management have been combined to propel diagnosis, treatment and long term care into a new era,” said Anthony Rosenzweig, MD. “This global gathering of top cardiovascular leaders will catalyze new connections, conversations and thinking around these opportunities.”
Among the many features of the Forum is announcement of the “Disruptive Dozen,” the technologies likely to have the greatest impact on cardiovascular and cardiometabolic care in the next decade.
The Forum will kick off with 10-minute rapid-fire presentations by Brigham and Women's Hospital and Massachusetts General Hospital's early career Harvard faculty leaders describing the clinical potential of their work. Discovery Café workshops will follow, led by senior Harvard faculty addressing cutting-edge cardiovascular challenges.
The World Medical Innovation Forum is organized by Partners HealthCare Innovation, a division of Partners HealthCare dedicated to advancing the commercial application of the unique capabilities of Partners’ Harvard faculty.
Sponsors of the Forum include Boston Scientific, Amgen, Lilly, GE, Pfizer, AstraZeneca, Bayer, Bard, Edwards Lifesciences, Mintz Levin, Medtronic and Novo Nordisk.